These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32519895)

  • 1. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
    Somanath PR
    Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L45-L47. PubMed ID: 32519895
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
    Dabaghian F; Khanavi M; Zarshenas MM
    Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
    [No Abstract]   [Full Text] [Related]  

  • 4. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.
    Dastan F; Abedini A; Shahabi S; Kiani A; Saffaei A; Zare A
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):10-12. PubMed ID: 32534505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
    South AM; Tomlinson L; Edmonston D; Hiremath S; Sparks MA
    Nat Rev Nephrol; 2020 Jun; 16(6):305-307. PubMed ID: 32246101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
    [No Abstract]   [Full Text] [Related]  

  • 7. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 8. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 9. Old and new antirheumatic drugs for the treatment of COVID-19.
    Benucci M; Damiani A; Infantino M; Manfredi M; Quartuccio L
    Joint Bone Spine; 2020 May; 87(3):195-197. PubMed ID: 32321635
    [No Abstract]   [Full Text] [Related]  

  • 10. Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
    Ali N
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):e84-e86. PubMed ID: 32471656
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of ACEIs/ARBs in COVID-19: Friend or foe?
    Zhou Z; Qiu Y; Tao J
    Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
    Şen S; Üresin AY
    Turk Kardiyol Dern Ars; 2020 Oct; 48(7):631-634. PubMed ID: 33034579
    [No Abstract]   [Full Text] [Related]  

  • 13. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential role of statins in COVID-19.
    Lee KCH; Sewa DW; Phua GC
    Int J Infect Dis; 2020 Jul; 96():615-617. PubMed ID: 32502659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
    Cadegiani FA
    Am J Physiol Endocrinol Metab; 2020 May; 318(5):E587-E588. PubMed ID: 32297520
    [No Abstract]   [Full Text] [Related]  

  • 16. [De første kliniske data fra RASi-behandlede indlagte patienter med COVID-19 kommer nu, og vi skal ikke ændre medicinering].
    Madsen PL
    Ugeskr Laeger; 2020 May; 182(20):. PubMed ID: 32400381
    [No Abstract]   [Full Text] [Related]  

  • 17. The therapeutic potential of targeting ACE2 in COVID-19.
    Elmorsi R
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9744-9747. PubMed ID: 33015820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage.
    Olsen M; Cook SE; Huang V; Pedersen N; Murphy BG
    Int J Antimicrob Agents; 2020 Jun; 55(6):105964. PubMed ID: 32251732
    [No Abstract]   [Full Text] [Related]  

  • 19. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
    Vikse J; Henry BM
    Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
    Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
    J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.